EP1379545A2 - Procede de production de series d'anticorps stables regenerables - Google Patents

Procede de production de series d'anticorps stables regenerables

Info

Publication number
EP1379545A2
EP1379545A2 EP02745239A EP02745239A EP1379545A2 EP 1379545 A2 EP1379545 A2 EP 1379545A2 EP 02745239 A EP02745239 A EP 02745239A EP 02745239 A EP02745239 A EP 02745239A EP 1379545 A2 EP1379545 A2 EP 1379545A2
Authority
EP
European Patent Office
Prior art keywords
antibody
protein
arrays
antibodies
producing stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02745239A
Other languages
German (de)
English (en)
Inventor
Jürgen WEHLAND
Ronald Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Publication of EP1379545A2 publication Critical patent/EP1379545A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier

Definitions

  • the invention relates to a method for producing stable, regenerable antibody arrays using immobilized antibody binding proteins which can specifically recognize the Fc part of antibodies.
  • Arrays with biological test molecules are also called biochips, particularly in miniaturized form. Proven examples of such arrays are:
  • Nucleic acid arrays from DNA fragments, cDNAs, RNAs, PCR products, plasmids, bacteriophages, synthetic oligonucleotides or synthetic PNA oligomers which are read out by means of hybridization (formation of a double-stranded molecule) on complementary nucleic acid analytes and connecting arrays made of synthetic ones Peptides, their analogs, such as peptoids, oligo-carbamates etc. or generally organic chemical compounds, which are read out by binding to affine protein or other analytes or by enzymatic conversion.
  • Such arrays are currently manufactured according to two different principles by placing the test molecules on already prepared material surfaces: a) by spreading the solution of pre-prepared test compounds once on the surface
  • Previously known chip configurations use either a right-angled x / y arrangement, which is produced with appropriately manufactured photolithography or printing masks, or a circular r ⁇ arrangement, which is generated by a rotational movement of the chip surface (r ⁇ -arrays) and a rapidly clocked metering device becomes. This enables densities of up to 1 million test connections per cm 2 or a few square micrometers per individual surface to be achieved.
  • the invention thus relates to a method for producing stable, regenerable antibody arrays, in which
  • the invention further relates to an antibody array which can be obtained by the method according to the invention, a medical or diagnostic device which has an antibody array according to the invention, and a kit which has an antibody array according to the invention and detection reagents for qualitative or quantitative determination contains bound antigens which have been bound to an antibody array according to the invention.
  • the invention further specifies the use of an antibody array according to the invention or a medical or diagnostic device according to the invention for the qualitative or quantitative determination of antigens.
  • Advantageous and / or preferred embodiments of the invention are the subject of the dependent claims.
  • the planar carrier has a surface made of glass, metal, metal oxides, semimetal oxides or plastic.
  • the antibody binding protein is selected from Fc-specific secondary antibodies, protein A and protein G.
  • the antigen to be determined is a protein.
  • the specific antibodies are "directed” immobilized, i.e. via their Fc part in order not to influence the antigen recognition through the coupling.
  • a grid of proteins that specifically recognize the Fc part of the specific antibodies is covalently bound to the chip surface in question (eg derivatized Fc-specific secondary antibodies or protein A or protein G molecules).
  • Protein / antibody or antibody / antibody complexes are achieved by chemical covalent crosslinking, where be used for common reagents according to the requirements.
  • chemical covalent crosslinking In addition to the stabilization of the protein-protein interactions, there is also an intramolecular stabilization of the specific antibodies, ie a chemical cross-linking of their subunits.
  • Antibody arrays with the highest stability result, which on the one hand prevent dissociation of the special antibodies, eg during storage, and on the other hand also make it possible to treat the antibody arrays under stringent conditions, such as high salt concentrations or low or high pH to prevent non-specific or low affinity interactions with the antibody matrix. This also enables a correspondingly stringent pretreatment of the protein mixtures to be analyzed.
  • the whole process delivers stable and regenerable antibody arrays.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de production de séries d'anticorps stables, régénérables, caractérisé en ce qu'on utilise des protéines immobilisées liant les anticorps et qui sont capables d'identifier spécifiquement la fraction Fc d'anticorps.
EP02745239A 2001-04-19 2002-04-18 Procede de production de series d'anticorps stables regenerables Withdrawn EP1379545A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10119308 2001-04-19
DE10119308 2001-04-19
DE10162365 2001-12-18
DE10162365 2001-12-18
PCT/EP2002/004311 WO2002085926A2 (fr) 2001-04-19 2002-04-18 Procede de production de series d'anticorps stables regenerables

Publications (1)

Publication Number Publication Date
EP1379545A2 true EP1379545A2 (fr) 2004-01-14

Family

ID=26009128

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02745239A Withdrawn EP1379545A2 (fr) 2001-04-19 2002-04-18 Procede de production de series d'anticorps stables regenerables

Country Status (4)

Country Link
US (1) US20040171068A1 (fr)
EP (1) EP1379545A2 (fr)
JP (1) JP2004536290A (fr)
WO (1) WO2002085926A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
ATE476494T1 (de) * 2003-02-24 2010-08-15 Pritest Inc Lichtdurchlässige festmatrix-prüfvorrichtung zur mikroarray-analyse
ATE428421T1 (de) * 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
JP4989476B2 (ja) * 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
CN104706637A (zh) * 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090156422A1 (en) * 2006-06-02 2009-06-18 Koninklijke Philips Electronics N.V. Device and method to detect analytes
WO2008026748A1 (fr) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
CA2676796C (fr) * 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition destinee au traitement d'un cancer de l'estomac de type indifferencie
US20100303813A1 (en) 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US8952035B2 (en) * 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2435827A1 (fr) * 2009-05-29 2012-04-04 The Board of Regents of The University of Texas System Ligands peptoïdes d'isolement et traitement de lymphocytes t auto-immuns
CA2764153C (fr) * 2009-06-02 2021-07-27 The Board Of Regents Of The University Of Texas System Identification de petites molecules reconnues par des anticorps chez des sujets atteints de maladies neurodegeneratives
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
US8759259B2 (en) * 2009-10-16 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for producing cyclic peptoid libraries
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
CN107428818A (zh) 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN119679944A (zh) 2018-01-25 2025-03-25 渤健马萨诸塞州股份有限公司 治疗脊髓性肌萎缩症的方法
CA3097025A1 (fr) 2018-04-13 2019-10-17 Incyte Corporation Biomarqueurs pour une maladie du greffon contre l'hote
EP3861347B1 (fr) 2018-10-05 2022-12-21 Eisai R&D Management Co., Ltd. Biomarqueurs pour une polythérapie comprenant du lenvatinib et de l'évérolimus
JP7564097B2 (ja) 2018-10-05 2024-10-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ソラフェニブ化合物を含む療法のためのバイオマーカー
US20220128578A1 (en) 2019-02-12 2022-04-28 Biogen Ma Inc. Biomarkers of progressive multifocal leukoencephalopathy
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
WO2021072098A1 (fr) 2019-10-10 2021-04-15 Incyte Corporation Biomarqueurs de la maladie du greffon contre l'hôte
EP4041204A1 (fr) 2019-10-10 2022-08-17 Incyte Corporation Biomarqueurs de la maladie du greffon contre l'hôte
EP4204546A1 (fr) 2020-08-31 2023-07-05 City of Hope Nouvelles lignées cellulaires, procédés de production de cellules tueuses naturelles et utilisations associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243040A (en) * 1987-11-20 1993-09-07 Creative Biomolecules DNA encoding a protein which enables selective removal of immune complexes
US5620845A (en) * 1988-06-06 1997-04-15 Ampcor, Inc. Immunoassay diagnostic kit
WO1997025616A1 (fr) * 1996-01-11 1997-07-17 Australian Membrane And Biotechnology Research Institute Groupage sanguin par capteur a canal ionique
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6713309B1 (en) * 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02085926A2 *

Also Published As

Publication number Publication date
WO2002085926A2 (fr) 2002-10-31
JP2004536290A (ja) 2004-12-02
US20040171068A1 (en) 2004-09-02
WO2002085926A3 (fr) 2003-11-06

Similar Documents

Publication Publication Date Title
EP1379545A2 (fr) Procede de production de series d'anticorps stables regenerables
DE19740263C2 (de) Kachelungsverfahren zum Bauen eines chemischen Arrays
DE102009012169B3 (de) Vorrichtung und Verfahren zum Herstellen eines Replikats oder eines Derivats aus einem Array von Molekülen und Anwendungen derselben
DE69812655T2 (de) Verfahren zum erstellen von arrays hoher dichte
DE60126319T2 (de) Immobilisierung von biopolymeren auf aminierten substraten durch direkte adsorption
EP1277055B1 (fr) Biopuce pour l'archivage et l'analyse en laboratoire medical d'un echantillon biologique
DE102004021351A1 (de) Funktionalisierter poröser Träger für Mikroarrays
EP2252410A2 (fr) Modification de surface
DE102011010307A1 (de) Vorrichtung und Verfahren zur Erzeugung von Protein-Mikroarrays
DE60213890T2 (de) Reaktionssondenchip und detektionssystem
DE60225593T2 (de) Immobilisierung von bindungsstoffen
DE112005003134T5 (de) Elektrisch aktiver kombinatorisch-chemischer (electrically-active combinatorial-chemical; eacc) Chip zur biochemischen Analytbestimmung
DE60130211T2 (de) Matrix-screening-verfahren
DE102004048685A1 (de) Verfahren zum Nachweis von Biopolymeren, Biochips, Verfahren zur Immobilisierung von Antikörpern und Substrate auf denen Antikörper immobilisiert sind
DE102004043870B4 (de) Verfahren zur Erweiterung des dynamischen Erfassungsbereich bei Mikroarrays
DE10126798A1 (de) Verfahren zur Bestimmung einer Probe
WO2007085403A2 (fr) Supports réticulables multifonction pour ligands (de faible poids moléculaire), leur utilisation en analytique et procédé de production et de réticulation desdits supports
EP1453959A2 (fr) Procede de selection et d'identification de molecules peptidiques ou proteiques par presentation a la surface de phages
EP1477809A1 (fr) Procédé pour imprimer des biomolécules
EP1451319A2 (fr) Procede d'identification de partenaires d'interaction au moyen de l'expression phagique
WO2007059839A1 (fr) Procede, dispositif et trousse pour l'analyse de macromolecules dans un echantillon
DE10340429A1 (de) Hydrophober Gegenstand mit Raster hydrophiler Bereiche, dessen Herstellung und Verwendung
EP1615717A1 (fr) Puce tridimensionnelle
DE19803077C1 (de) Verfahren zur Herstellung von Testkörpern zum spezifischen Nachweis einzelner Reaktanden von Rezeptorsubstanz-Ligandensubstanz Komplexen
WO2008080531A2 (fr) Procédé, dispositif et kit pour l'examen d'un échantillon de liquide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031014

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20050401